Holly Wilhalme

Dec 23, 2024 | acrjournals.onlinelibrary.wiley.com | Elizabeth R Volkmann |Holly Wilhalme |Donald Tashkin |Jonathan Goldin |Alana Haussmann |Masataka Kuwana | +2 more

Supporting Information Filename Description acr25485-sup-0001-Disclosureform.pdfPDF document, 671.5 KB Disclosure Form acr25485-sup-0002-supinfo.docxWord 2007 document , 331.1 KB Supporting Information

May 7, 2024 | digitalcommons.library.tmc.edu | Elizabeth R Volkmann |Holly Wilhalme |Shervin Assassi |Jonathan Goldin

OBJECTIVE: Progressive pulmonary fibrosis (PPF) is the leading cause of death in systemic sclerosis (SSc). This study aimed to develop a clinical prediction nomogram using clinical and biological data to assess risk of PPF among patients receiving treatment of SSc-related interstitial lung disease (SSc-ILD). METHODS: Patients with SSc-ILD who participated in the Scleroderma Lung Study II (SLS II) were randomized to treatment with either mycophenolate mofetil (MMF) or cyclophosphamide (CYC).

Aug 18, 2023 | acrjournals.onlinelibrary.wiley.com | Elizabeth R Volkmann |Holly Wilhalme |Shervin Assassi |Jonathan Goldin

INTRODUCTION Progressive pulmonary fibrosis (PPF) is the leading cause of death in patients with systemic sclerosis (SSc) (1). Although interstitial lung disease (ILD) occurs in the majority of patients with SSc (2), the disease course can vary considerably between patients (3). Recent observational studies have demonstrated that approximately one third of patients with SSc-ILD experience PPF at 1 year (4). However, predicting which patients with SSc-ILD will develop PPF remains a challenge (3).